Contents of this document
- Operating profit for the fiscal year ended March 2025¥3.04 billion
- Change in operating profit+¥0.4 billion
- Operating profit, fiscal year ended March 2026¥3.45 billion
- Capital investment to increase ammonium perchlorate production
- Investment in manufacturing facilities for solid propellants for defense applications (¥7 billion, scheduled for completion in fiscal 2027)
- Upgrade the PET line from the hot-fill method to the aseptic method
- Research and development and mass production of solid propellants, and business expansion into related areas
- Additional business development investment focused on priority areas
- Employee Engagement63.5 %
- PBR1.42 timesYear on year against the same period last yearImproved from 0.66x
- ROE7.7 %Year on year against the same period last yearImproved from 6.9%
- ChemicalsNet Sales¥21,977 million (YoY -2.0%)Operating profit¥1,858 million (YoY +25.7%)
- BottlingNet Sales¥4,480 million (YoY -1.0%)Operating profit¥378 million (YoY +9.6%)
- Metal ProcessingNet Sales¥7,303 million (YoY +1.0%)Operating profit¥602 million (YoY +18.5%)
- Engineering ServicesNet Sales¥5,251 million (YoY +19.0%)Operating profit¥795 million (YoY -3.3%)
- TargetOperating profitTarget value¥4.2 billionTarget fiscal yearFY2027
- TargetPBRTarget value2x or moreTarget fiscal yearFiscal year ending March 2028
- TargetROETarget value8.5%Target fiscal yearFiscal year ending March 2028
- TargetEmployee EngagementTarget value6.5 percentage-point increase from the fiscal 2025 actual of 63.5%Target fiscal yearFY2027
- ROETarget value8.5%Actual value7.7%
- PBRTarget value2x or moreActual value1.42x
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | ¥36,247 million (YoY -1.8%) |
| Operating profit | ¥3,459 million (YoY +13.5%) |
| Ordinary income | ¥3,755 million (YoY +13.1%) |
| Net income | ¥2,976 million (YoY +15.8%) |
| Selling, general and administrative expenses | ¥6,073 million |
| Full-year earnings forecast | Net Sales ¥37,200 million / Operating profit ¥3,200 million / Ordinary income ¥3,300 million / Net income ¥3,000 million / Year-end dividend ¥42 per share |
| Segment results | Segment Chemicals / Net Sales ¥21,977 million (YoY -2.0%) / Operating profit ¥1,858 million (YoY +25.7%), Segment Bottling / Net Sales ¥4,480 million (YoY -1.0%) / Operating profit ¥378 million (YoY +9.6%), Segment Metal Processing / Net Sales ¥7,303 million (YoY +1.0%) / Operating profit ¥602 million (YoY +18.5%), Segment Engineering Services / Net Sales ¥5,251 million (YoY +19.0%) / Operating profit ¥795 million (YoY -3.3%) |
| Breakdown of Factors Affecting the Change | Factors Operating profit for the fiscal year ended March 2025 / Amount ¥3.04 billion, Factors Change in operating profit / Amount +¥0.4 billion, Factors Operating profit, fiscal year ended March 2026 / Amount ¥3.45 billion |
| Key KPIs | Indicator name Employee Engagement / Value 63.5 % / Year on year against the same period last year Not disclosed, Indicator name PBR / Value 1.42 times / Year on year against the same period last year Improved from 0.66x, Indicator name ROE / Value 7.7 % / Year on year against the same period last year Improved from 6.9% |
| Medium-term management plan targets | Target Operating profit / Target value ¥4.2 billion / Target fiscal year FY2027, Target PBR / Target value 2x or more / Target fiscal year Fiscal year ending March 2028, Target ROE / Target value 8.5% / Target fiscal year Fiscal year ending March 2028, Target Employee Engagement / Target value 6.5 percentage-point increase from the fiscal 2025 actual of 63.5% / Target fiscal year FY2027 |
| Financial targets | Indicator ROE / Target value 8.5% / Actual value 7.7%, Indicator PBR / Target value 2x or more / Actual value 1.42x |
| Annual Dividend | Annual dividend per share ¥42 per share / Interim Not disclosed / End of period ¥42 per share |
| Acquisition of treasury shares | Buyback limit ¥1 billion / Period May 2026 |
| Capital expenditures | 210 Hundreds of millions of yen |
| New initiatives | Capital investment to increase ammonium perchlorate production, Investment in manufacturing facilities for solid propellants for defense applications (¥7 billion, scheduled for completion in fiscal 2027), Upgrade the PET line from the hot-fill method to the aseptic method, Research and development and mass production of solid propellants, and business expansion into related areas, Additional business development investment focused on priority areas |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, reflecting appropriate prices in sales companies, cost reductions and productivity improvements contributed to higher profit. On the other hand, sales of certain products and in some areas declined due to slower EV demand, adjustments by certain customers, and lower demand from the paper and pulp, automotive and steel industries. For the fiscal year ending March 2027, the company expects production capacity to be constrained by the renewal of bottling equipment, uncertainty and higher costs in procuring raw materials and fuel due to the situation in the Middle East, and intensifying competition in engineering services.